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Abstract 
In view of the certain anatomic site dependent frequency of chromosomal translocations 
involved in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue 
(MALT lymphoma) pathogenesis, 17 salivary gland MALT lymphoma cases were analyzed 
for MALT1 and FOXP1 translocations. 
BCL10 and FOXP1 protein expression were studied by immunohistochemistry and 
translocations identified using fluorescence in situ hybridization (FISH)-specific probes 
FOXP1, t(11;18)(q21;q21)/API2-MALT1 and  t(14;18)(q32;q21)/IgH-MALT1. 
None of the 11 analyzed cases showed FOXP1 rearrangement or amplification. The t(11;18) 
was present in five of 13 cases and the t(14;18) in three of 13  cases. MALT1 translocations 
were mostly mutually exclusive except in a single case. FOXP1 protein expression showed 
differences in the proportion of tumor cells with nuclear expression but not in their intensity, 
with the exception of one case where very intense nuclear staining was noted. BCL10 nuclear 
expression was present in four of 17 cases, two of which lacked the t(11;18). 
Our results suggest that MALT1 specific translocations and FOXP1 rearrangements are not 
commonly involved in pathogenesis. A case with strong FOXP1 protein expression indicates 
the possibility that the up-regulation of FOXP1 expression is significant in a small subset of 
salivary gland MALT lymphomas. Also a single case where both MALT1 translocations were 
present indicates that these are not always mutually exclusive.  
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Introduction 
Extranodal marginal zone B cell lymphoma of  mucosa associated lymphoid tissue (MALT 
lymphoma) is recognized as a distinct clinicopathological entity in the World Health 
Organization (WHO) classification of malignant lymphomas and constitutes 8% of all Non 
Hodgkin lymphomas (NHL).1 The disease is generally indolent and localized but can  
transform into a more aggressive diffuse large B cell lymphoma (DLBCL). MALT 
lymphomas most often occur in the stomach (70%) or less commonly in other extranodal sites 
such as the salivary glands, lungs, ocular adnexa and thyroid among others.2-4   
Primary NHL constitute 2-5% of salivary glands malignant lesions and represent an 
uncommon tumor.5 Morphological characteristics are  the basis of classification of 
lymphoproliferative lesions in the salivary glands.5-7 Immunophenotypic analysis of aberrant 
phenotype and flow cytometric or molecular genetic analysis of immunoglobulin light chain 
restriction are useful methods to support a diagnosis of malignant lymphoma.5,8,9 MALT 
lymphomas occur most often in organs where organized lymphatic tissue is normally absent 
and usually arise from MALT that has been acquired as a result of a chronic inflammatory 
disorder.2,3 In the salivary gland, MALT lymphomas are usually preceded by 
lymphoepithelial sialadenitis, often  associated with Sjögren's syndrome.5  
Three well characterized chromosomal translocations t(11;18)(q21;q21), t(1;14)(p22;q32) and 
t(14;18)(q32;q21) are implicated in the pathogenesis of MALT lymphoma. Also, the specific 
translocations occur at variable frequencies in MALT lymphomas from different anatomical 
sites, t(11;18)(q21;q21) and t(1;14)(p22;q32) more often in gastrointestinal and pulmonary 
lesions and t(14;18)(q32;q21) in salivary glands, skin, ocular adnexa and liver lesions.10-13 
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The t(11;18)(q21;q21) translocation is most common, occurring in 15-40% of cases, and 
results in a fusion of the API2 and MALT1 genes. The t(1;14)(p22;q32) translocation, detected 
in 1-2% of cases, results in overexpression of the BCL10 gene. Moreover, this translocation 
alters the subcellular localization of BCL10 and cases with either the t(1;14) or the t(11;18) 
show strong nuclear BCL10 expression, rather than the cytoplasmic expression seen in 
normal germinal centre B cells.14 The t(14;18)(q32;q21) translocation, described in 20% of 
cases, juxtaposes the MALT1 gene and the IgH locus  and thus deregulates its expression.15  
FOXP1 is located within a human tumor suppressor locus at 3p14.1 and its expression is 
deregulated in a number of tumours.16  The recently described t(3;14)(p14;q32) identified the 
FOXP1 forkhead transcription factor as recurrent translocation partner involving the enhancer 
region of the IgH locus to deregulate gene expression in MALT lymphoma.17 This 
translocation was detected in MALT lymphomas arising at certain anatomic sites: skin, 
thyroid and ocular adnexa.17 In addition, Wlodarska and colleagues also described  the 
t(3;14)(p14;q32) in gastric MALT lymphoma and initial data suggest that the FOXP1 
translocation occurs mutually exclusively with the three specific MALT lymphoma 
associated translocations.17,18   
The pathogenetic relevance of t(3;14)(p14;q32), trisomy of chromosome 3 and FOXP1 
protein expression is still unclear  but recent data indicate FOXP1 expression predicts poor 
prognosis and transformation to DLBCL in MALT lymphomas.18,19 In view of the certain 
anatomic site dependent frequency of chromosomal translocations involved in MALT 
lymphoma pathogenesis we have analyzed the frequency of  FOXP1 gene rearrangement and 
its relationship with patterns of FOXP1 protein expression in salivary gland MALT 
lymphoma. In parallel we have also examined cases for the most common MALT1 
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translocations t(11;18)(q21;q21) and t(14;18)(q32;q21), and for BCL10 protein expression in 
an attempt to elucidate the molecular mechanisms involved in salivary gland MALT 
lymphoma pathogenesis.  
 
Methods and materials 
Surgically resected parotid or submandibular salivary glands, diagnosed with MALT 
lymphoma (n=17), presenting at Merkur University Hospital between 1992-2004 were used 
with ethical approval and patient consent. Cases were processed routinely with H&E, Giemsa 
and analyzed according to the WHO classification diagnostic criteria by a qualified 
pathologist (MD).1 All cases were immunohistochemicaly CD20 positive and CD3, CD5 and 
CD10 negative with the exception of five cases which were CD5 cytoplasmic positive (data 
not shown).4 The B cell monoclonality in all cases was confirmed by polymerase chain 
reaction according to the BIOMED 2 protocol (data not shown).20  Deparaffinized tissue 
sections (4 µm thick) were immunostained for BCL10 (Zymed Laboratories Corporation, San 
Francisco, CA, USA) and FOXP1  (JC12 monoclonal antibody provided by AHB, Nuffield 
Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK).16 Heat 
induced antigen retrieval by pressure cooking treatment (Pascal, Dako, Glostrup, Denmark) 
was performed, for BCL10 in 0.01M sodium citrate buffer pH6, at 125ºC, 30 seconds and for 
JC12 antibody in 1mM EDTA solution pH8, at 125ºC, 30 seconds. The universal labeled 
streptavidin biotin kit LSAB (Dako) was used to visualize BCL10 expression and the HRP+ 
(Dako) for JC12 labeling. Sections were stained in an Autostainer (Dako) and counterstained 
with hematoxylin. 
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Tissues were also analyzed using dual fusion fluorescence in situ hybridization (FISH) 
assays: t(14;18)(q32;q21)/IgH-MALT1, t(11;18)(q21;q21)/API2-MALT1 (Abott Diagnostics, 
Abbott Park, IL, USA) and a FOXP1 probe as previously  described.21,22 The gastric MALT 
lymphoma cases with t(14;18) and t(11;18) translocations and primary nodal DLBCL cases 
with FOXP1 rearrangements were used as positive controls in our laboratory. In some cases 
FISH analysis or immunostaining were not performed due to poor tissue processing or 
insufficient quantities of material. 
 
Results 
Results of the FISH analysis of chromosomal translocations t(11;18)(q21;q21)/API2-MALT1, 
t(14;18)(q32;q21)/IgH-MALT1, FOXP1 rearrangements and immunostaining for BCL10 and 
FOXP1 protein expression in salivary gland MALT lymphomas are described in Table 1.  
The BCL10 immunolabeling demonstrated cytoplasmic BCL10 protein expression in all 17 
cases and nuclear positivity within the tumor cells was also present in four of these cases. 
Immunohistochemical staining with JC12 in 11 of 17 cases showed that two cases lacked 
FOXP1 protein expression in the tumor cells and five cases showed nuclear positivity in 10-
30% of the tumor cells (score 1). In the remaining four cases FOXP1 protein was observed in 
nuclei in more than 30% of tumor cells (score 2). The intensity of JC12 staining was 
generally weak; however, one case (no.12) did exhibit very intense nuclear FOXP1 protein 
expression.  
Eleven cases were suitable for analysis by FISH using the FOXP1 specific breakapart probe 
and all were negative for FOXP1 rearrangements. None of the cases showed FOXP1 
amplifications or trisomy 3. Primary nodal DLBCL cases from Merkur University Hospital 
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have been found to contain FOXP1 translocations, confirming the ability of this probe to 
detect these rearrangements in our laboratory. Analysis for the MALT1 translocations was 
successful in 13 cases. The API2-MALT1 rearrangement, t(11;18)(q21;q21), was identified in 
five of 13 (38.5%) cases, and the t(14;18)(q32;q21)/IgH-MALT1 in three of 13 (23.1%) cases.  
The results of compared FISH analysis and immunostaining for BCL10 and FOXP1 protein 
expression (Figure 1) showed the two of four cases with nuclear BCL10 harbored the 
t(11;18)(q21;q21) and the remaining two BCL10 nuclear cases lacked the API2-MALT1 
rearrangement. The t(11;18)(q21;q21) and t(14;18)(q32;q21) translocations or BCL10 nuclear 
staining were absent in three of the four cases  with nuclear FOXP1 expression in more than 
30% of tumor cells. This was consistent with the finding that four of the five cases with the 
MALT1 translocations or BCL10 nuclear expression had FOXP1 nuclear expression in 10-
30% of tumor cells.   
 
Discussion 
Although, Streubel and colleagues suggested clustering of t(3;14)(p14;q32) at certain 
anatomical sites and reported that MALT lymphomas arising in the stomach, salivary gland 
and lung were negative. Wlodarska and colleagues have shown a gastric MALT lymphoma 
case with this translocation.17,18 Also Streubel and colleagues selected primary MALT 
lymphoma cases without known translocations to look for FOXP1 translocation and studied 
fewer cases with the known translocations to determine their mutual exclusivity.17  
The FISH analysis for translocations involving MALT1 show a lower frequency of 
IgH-MALT1 rearrangements  (23.1% of cases) compared to the more common API2-MALT1 
fusion (38.5% of cases) in analyzed MALT lymphomas presenting in salivary glands. 
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According to the literature,  the t(14;18)(q32;q21) is found in 20% of salivary gland MALT 
lymphomas and   the t(11;18)(q21;q21) in approximately 40% of gastric and lung MALT 
lymphomas, but this frequency is lower in salivary gland and orbital MALT lymphomas.11-
13,23-25
 Although the t(11;18)(q21;q21) is more commonly present in gastric and pulmonary 
MALT lymphomas, the frequency of 1-6% in salivary gland MALT lymphomas is 
described.11,12  The high frequency of API2-MALT1 fusion observed in the present study of 
salivary gland MALT lymphomas could be due to the small number of cases.  
According to the literature four recurrent translocations t(11;18)(q21;q21), 
t(1;14)(p22;q32), t(14;18)(q32;q21) and t(3;14)(p14;q32) occur mutually exclusively in 
MALT lymphomas.13,17,26 The two analyzed MALT1 translocations in the present study were 
mutually exclusive except in a single case (no. 16) where both translocations were present. To 
the best of our knowledge this is the first report showing the presence of both translocations 
in the same case. Clinically this women (57 years old) presented with unilateral enlargement 
of the parotid gland. Pathohistological examination of surgically resected parotid gland 
resulted in a diagnosis of MALT lymphoma without peripheral blood and bone marrow 
infiltration. Also chronic Helicobacter pylori positive gastritis and autoimmune leucopenia 
were diagnosed. After surgical resection the patient is still well without any disease 
symptoms in the follow up period of 36 months.  
Compering the clinical course of patient no.16 with both MALT1 translocations and three of 
six patients (no. 4,11,17) with t(11;18) or t(14;18) and available clinical data no differences in 
clinical course were observed. Also no differences in clinical course were observed in four of 
eight patients (no. 4,11,15,17) with MALT1 translocations and/or BCL10 nuclear expression 
and the one patient (no. 13) lacking MALT1 translocations and BCL10 nuclear expression. In 
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the follow up period between 12-50 months the patients presented with local disease and any 
additional therapy after surgical resection was applied.  
BCL10 is strongly expressed in the nuclei of MALT lymphoma cells with 
t(1;14)(p22;q32) and t(11;18)(q21;q21), and in the cytoplasm of normal germinal centre B 
cells and in MALT lymphoma cells with t(14;18)(q32;q21).3 In line with observations that 
aberrant nuclear expression may play a role in the development of MALT lymphoma, in  two 
cases with evident BCL10 nuclear expression and absent API2-MALT1 rearrangement the 
presence of t(1;14)(p22;q32) could be inferred.3,5,27 However, there is currently no 
commercial FISH probe available to enable us to confirm this. 
Our results demonstrate the absence of FOXP1 rearrangements in salivary gland 
MALT lymphomas. The absence of this translocation in cases harboring MALT1 
translocations confirms previous findings.17 In cases that lacked FOXP1 expression in more 
than 30% of the tumor cells we commonly observed MALT1 translocations and/or BCL10 
nuclear expression. This may suggest that in cases with activation of the BCL10/MALT1 
pathway FOXP1 has a limited role in disease development. Through analysis of FOXP1 
protein expression in MALT lymphoma, we observed differences in the proportion of tumor 
cells with nuclear expression but not in the intensity of nuclear positivity with the exception 
of a single case with strong nuclear FOXP1 staining. This case did not exhibit a 
rearrangement of the FOXP1 gene or display trisomy 3 / amplification of the FOXP1 locus. 
Thus alternative mechanisms are implicated in up regulating FOXP1 expression in a subset of 
MALT lymphomas. Because only two of four cases showing higher proportion of tumor cells 
with FOXP1 protein expression were able to be examined with FOXP1 FISH probe, the 
relationship between FOXP1 rearrangements and protein expression in these cases is unclear. 
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Salivary gland MALT lymphomas lack FOXP1 rearrangements suggesting that these 
are not commonly involved in the pathogenesis of MALT lymphomas at this anatomical site 
that lack MALT1 specific translocations. The finding of a case with strong intensity of FOXP1 
protein expression indicates the possibility that up regulation of FOXP1 expression by 
alternative mechanisms may yet play a role in a small subset of salivary gland MALT 
lymphomas. Also a single case where both MALT1 translocations were present indicates that 
these are not always mutually exclusively presented in MALT lymphomas. 
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Table 1 FISH analysis and immunostaining in salivary gland MALT lymphomas 
 
API2, BIRC 3 baculoviral IAP repeat-containing 3; BCL10, B cell CLL/lymphoma 10; 
FOXP1, forkhead box P1; MALT, mucosa-associated lymphoid tissue; ND, not done due 
to poor tissue processing or insufficient quantities of material; 
+, rearrangement present; -, rearrangement absent,  
c +,  cytoplasmic positive; n +, nuclear positive;  
0, negative JC12 staining; 1,  nuclear JC12 staining in 10-30% of tumor cells; 2,  nuclear 
JC12 staining in >30% of tumor cells; +, weak intensity of nuclear FOXP1 protein 
expression; ++, strong intensity of nuclear FOXP1 protein expression. 
 
 
                        FISH analysis                Immunostaining 
Patient t(11;18)(q21;q21)
/ API2-MALT1 
 
t(14;18)(q32;q21)
/ IgH-MALT1 
FOXP1 
 
 BCL10 JC12  
1 - + -  c +     0 
2 ND ND ND  c + 2 + 
3 ND ND ND  c + 2 + 
4 + - -  c +   n + 1 + 
5 - + -  c +    ND 
6 - - ND  c + ND 
7 - - -  c +    2 + 
8 ND - ND  c + ND 
9 ND ND ND  c +     0 
10 - - ND  c +   n + ND 
11 + - -  c + 1 + 
12 + - -  c +   n +   2 ++ 
13 - - -  c +    1 + 
14 - - -  c + ND 
15 - - -  c +   n + 1 + 
16 + + -  c + 1 + 
17 + ND -  c + ND 
Figure legends 
 
Figure 1 
(a) FISH, salivary gland MALT lymphoma, case 11, probe for detection t(11;18)(q21;q21)/API2- MALT1. Fused signals represent 
translocations, red signal, the MALT1 gene and green signal, the API2 gene. 
(b) MALT lymphoma of the salivary gland, case 12, nuclear expression of BCL 10. 
(c) MALT lymphoma of the salivary gland, case 13, weak intensity of nuclear FOXP1 protein expression. 
(d) MALT lymphoma of the salivary gland, case 12, strong intensity of nuclear FOXP1 protein expression. 
 
